ALLOCAR T

Serial Number 97889420
Registration 7307152
790

Registration Progress

Application Filed
Apr 14, 2023
Under Examination
Approved for Publication
Published for Opposition
Registered
Feb 13, 2024

Trademark Image

ALLOCAR T

Basic Information

Serial Number
97889420
Registration Number
7307152
Filing Date
April 14, 2023
Registration Date
February 13, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
790
Status Date
Aug 30, 2024
Registration
Registered
Classes
005

Rights Holder

Allogene Therapeutics, Inc.

03
Address
210 E. Grand Avenue
South San Francisco, CA 94080

Ownership History

Allogene Therapeutics, Inc.

Original Applicant
03
South San Francisco, CA

Allogene Therapeutics, Inc.

Original Registrant
03
South San Francisco, CA

Legal Representation

Attorney
THOMAS L. HOLT

USPTO Deadlines

Next Deadline
1673 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-02-13)
Due Date
February 13, 2030
Grace Period Ends
August 13, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

12 events
Date Code Type Description Documents
Aug 30, 2024 PETC T CANCELLATION INSTITUTED NO. 999999 Loading...
Feb 13, 2024 NRCS E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Feb 13, 2024 R.SR A REGISTERED-SUPPLEMENTAL REGISTER Loading...
Jan 10, 2024 CNTA O APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Loading...
Jan 10, 2024 LOPR P LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN Loading...
Jan 10, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 31, 2023 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Dec 31, 2023 ALIE A ASSIGNED TO LIE Loading...
Aug 2, 2023 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Jun 28, 2023 LOPT I LETTER OF PROTEST EVIDENCE FORWARDED Loading...
May 9, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 18, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy
First Use Anywhere: Jul 13, 2021
First Use in Commerce: Jul 13, 2021

Classification

International Classes
005